Sanofi Pasteur is reporting positive results from its investigational vaccine targeting Clostridium Difficile.  In phase II trials, Sanofi's vaccine met key objectives.  It was reported in the study and most participants experienced mild reaction to the vaccine.  Essentially, the vaccine targets two toxins associated with C. Diff. infections.